Chemotherapy, Cancer, Regional Perfusion
"Chemotherapy, Cancer, Regional Perfusion" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Neoplasm drug therapy involving an extracorporeal circuit with temporary exclusion of the tumor-bearing area from the general circulation during which high concentrations of the drug are perfused to the isolated part.
| Descriptor ID |
D010478
|
| MeSH Number(s) |
E02.319.267.200 E04.292.425
|
| Concept/Terms |
Chemotherapy, Cancer, Regional Perfusion- Chemotherapy, Cancer, Regional Perfusion
- Regional Perfusion Antineoplastic Chemotherapy
- Isolation Perfusion Cancer Chemotherapy
- Cancer Chemotherapy, Regional Perfusion
- Perfusion Cancer Chemotherapy, Regional
- Regional Perfusion Cancer Chemotherapy
|
Below are MeSH descriptors whose meaning is more general than "Chemotherapy, Cancer, Regional Perfusion".
Below are MeSH descriptors whose meaning is more specific than "Chemotherapy, Cancer, Regional Perfusion".
This graph shows the total number of publications written about "Chemotherapy, Cancer, Regional Perfusion" by people in this website by year, and whether "Chemotherapy, Cancer, Regional Perfusion" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 2 | 0 | 2 |
| 2017 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemotherapy, Cancer, Regional Perfusion" by people in Profiles.
-
A total neoadjuvant chemotherapy approach is associated with improved recurrence-free survival in patients with colorectal peritoneal metastases undergoing cytoreductive surgery and HIPEC. J Surg Oncol. 2023 Mar; 127(3):442-449.
-
Safety and Clinical Value of Prophylactic Ureteral Stenting Before Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy. Am Surg. 2023 May; 89(5):1436-1441.
-
Diagnostic Laparoscopy in Patients With Peritoneal Carcinomatosis Is Safe and Does Not Delay Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy. Am Surg. 2022 Apr; 88(4):698-703.
-
Primary Tumor Sidedness is Predictive of Survival in Colon Cancer Patients Treated with Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: A US HIPEC Collaborative Study. Ann Surg Oncol. 2019 Jul; 26(7):2234-2240.
-
Core Body Temperature but Not Intraabdominal Pressure Predicts Postoperative Complications Following Closed-System Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Administration. Ann Surg Oncol. 2018 Mar; 25(3):660-666.
-
A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol. 2016 May; 23(5):1609-17.
-
Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for children, adolescents, and young adults: the first 50 cases. Ann Surg Oncol. 2015 May; 22(5):1726-32.
-
Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2015 May; 22(5):1716-21.
-
Complete cytoreduction and HIPEC improves survival in desmoplastic small round cell tumor. Ann Surg Oncol. 2014 Jan; 21(1):220-4.
-
Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol. 2014 May; 21(5):1501-5.